INT89336

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2000
Last Reported 2007
Negated 0
Speculated 0
Reported most in Abstract
Documents 6
Total Number 6
Disease Relevance 1.75
Pain Relevance 2.63

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (SP3) intracellular (SP3) DNA binding (SP3)
Anatomy Link Frequency
proximal 1
SP3 (Homo sapiens)
Pain Link Frequency Relevance Heat
narcan 3 96.76 Very High Very High Very High
antagonist 3 96.36 Very High Very High Very High
Cholecystokinin 7 96.12 Very High Very High Very High
mu opioid receptor 18 95.92 Very High Very High Very High
cINOD 11 93.28 High High
agonist 3 93.04 High High
Enkephalin 3 91.72 High High
Opioid 3 85.96 High High
metalloproteinase 2 83.52 Quite High
withdrawal 1 77.84 Quite High
Disease Link Frequency Relevance Heat
Pancreatic Cancer 4 98.90 Very High Very High Very High
Alcohol Addiction 3 92.00 High High
Lung Cancer 1 86.44 High High
INFLAMMATION 3 85.12 High High
Repression 1 84.96 Quite High
Cancer 3 82.00 Quite High
Colon Cancer 1 79.72 Quite High
Panic Disorder 3 79.24 Quite High
Substance Withdrawal Syndrome 1 78.20 Quite High
Schizophrenia 1 70.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Electrophoretic mobility shift assays show that Sp1 and Sp3 proteins constitutively bind to this consensus sequence and overexpression of Sp1 may enhance MMP-2 expression.
Sp3 Binding (bind) of
1) Confidence 0.47 Published 2002 Journal J. Biol. Chem. Section Abstract Doc Link 12087091 Disease Relevance 0.33 Pain Relevance 0.80
Sp1 and Sp3 bound to this 60 bp region, which was confirmed by electromobility shift assays using a Sp1 consensus oligo as competitor and specific antibodies against Sp1 and Sp3.
Sp3 Binding (bound) of
2) Confidence 0.47 Published 2001 Journal Gene Section Abstract Doc Link 11675004 Disease Relevance 0 Pain Relevance 0.58
Such enhanced binding of Sp1/Sp3 to the promoter may lead to a functional change in hMOR gene transcription.
Sp3 Binding (binding) of
3) Confidence 0.47 Published 2001 Journal Gene Section Abstract Doc Link 11675004 Disease Relevance 0 Pain Relevance 0.36
We demonstrate that substitution of the C-36 residue causes a slight reduction of Sp1 and Sp3 binding, but this has no effect on transcription in vivo.
Sp3 Binding (binding) of
4) Confidence 0.43 Published 2000 Journal Mol. Psychiatry Section Abstract Doc Link 10889557 Disease Relevance 0.76 Pain Relevance 0.39
Taken together, the present studies demonstrated, for the first time, that the binding of Sp1/Sp3 to the hMOR proximal promoter could be modulated by chronic DAMGO treatment.
Sp3 Binding (binding) of in proximal
5) Confidence 0.35 Published 2001 Journal Gene Section Abstract Doc Link 11675004 Disease Relevance 0 Pain Relevance 0.41
Comparable results were obtained in pancreatic cancer cells transfected with small inhibitory RNAs for Sp1, Sp3, and Sp4 and all three proteins bound to GC-rich elements in the VEGFR1 promoter.
Sp3 Binding (bound) of associated with pancreatic cancer
6) Confidence 0.04 Published 2007 Journal Cancer Res. Section Abstract Doc Link 17409437 Disease Relevance 0.66 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox